Key result
Higher plasma PENK concentrations were initially associated with a higher risk of new-onset heart failure (HR 2.09; 95% CI 1.47-2.97; p<0.001), but this association was lost after adjusting for eGFR.
Why the study?
The association between plasma proenkephalin (PENK) concentrations and new-onset heart failure in the general population remained to be established.
Are plasma proenkephalin (PENK) concentrations associated with new-onset heart failure in the general population?
Cohort (n=6,677)
Are plasma proenkephalin (PENK) concentrations associated with new-onset heart failure in the general population?
Hazard Ratio: 2.09 (95% CI 1.47–2.97)
p-value: p=< .001
Plasma proenkephalin concentrations are not independently associated with new-onset heart failure in the general population, as the relationship is primarily confounded by renal function (eGFR).
May flag elevated HF risk in the general population; leaves open added value beyond established predictors.
BACKGROUND: Enkephalins of the opioid system exert several cardiorenal effects. Proenkephalin (PENK), a stable surrogate, is associated with heart failure (HF) development after myocardial infarction and worse cardiorenal function and prognosis in patients with HF. The association between plasma PENK concentrations and new-onset HF in the general population remains to be established. HYPOTHESIS: We hypothesized that plasma PENK concentrations are associated with new-onset HF in the general population. METHODS: We included 6677 participants from the prevention of renal and vascular end-stage disease study and investigated determinants of PENK concentrations and their association with new-onset HF (both reduced [HFrEF] and preserved ejection fraction [HFpEF]). RESULTS: Median PENK concentrations were 52.7 (45.1-61.9) pmol/L. Higher PENK concentrations were associated with poorer renal function and higher NT-proBNP concentrations. The main determinants of higher PENK concentrations were lower estimated glomerular filtration rate (eGFR), lower urinary creatinine excretion, and lower body mass index (all p < .001). After a median 8.3 (7.8-8.8) years follow-up, 221 participants developed HF; 127 HFrEF and 94 HFpEF. PENK concentrations were higher in subjects who developed HF compared with those who did not, 56.2 (45.2-67.6) versus 52.7 (45.1-61.6) pmol/L, respectively (p = .003). In competing-risk analyses, higher PENK concentrations were associated with higher risk of new-onset HF (hazard ratio [HR] = 2.09[1.47-2.97], p < .001), including both HFrEF (HR = 2.31[1.48-3.61], p < .001) and HFpEF (HR = 1.74[1.02-2.96], p = .042). These associations were, however, lost after adjustment for eGFR. CONCLUSIONS: In the general population, higher PENK concentrations were associated with lower eGFR and higher NT-proBNP concentrations. Higher PENK concentrations were not independently associated with new-onset HFrEF and HFpEF and mainly confounded by eGFR.
No takes yet. Share an insight, caveat, or question.
Emmens et al. (2021) conducted a cohort in new-onset heart failure (n=6,677). Plasma proenkephalin (PENK) concentrations vs. Lower PENK concentrations was evaluated on new-onset HF (HR 2.09, 95% CI 1.47-2.97, p=< .001). Higher plasma PENK concentrations were initially associated with a higher risk of new-onset heart failure (HR 2.09; 95% CI 1.47-2.97; p<0.001), but this association was lost after adjusting for eGFR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: